Medical News

RSS

Companies get help to insure early retirees

Reporting for Kaiser Health News and USA Today, KHN staff writer Christopher Weaver reports: "The White House unveiled details last week of a $5 billion program to provide financial relief to companies that offer health coverage to early retirees.

10 May 2010

CHRISTUS Health selects Wolters Kluwer Health's ProVation Order Sets electronic solution

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that CHRISTUS Health has selected ProVation® Order Sets, powered by UpToDate® Decision Support, as its electronic order set solution. In addition to automating development and maintenance, ProVation Order Sets will provide clinicians at 24 CHRISTUS facilities with point-of-care access to order sets and other intuitive clinical decision support tools.

10 May 2010

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Competitive Technologies, Inc. announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment.

10 May 2010

Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has achieved enrolled of over 400 subjects in its pivotal global Phase III study of its flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product designed to replace prandial injections of insulin.

10 May 2010

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

IQuum, Inc. today announced it has been granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Liat™ Influenza A/2009 H1N1 Assay. The assay detects and differentiates 2009 H1N1 influenza viral RNA starting from collected nasopharyngeal swab samples in less than 30 minutes.

10 May 2010

Eisai enters Canadian pharmaceutical market

Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.

10 May 2010

Companies await health IT windfall

The Washington Post: A Virginia firm, Vangent, is positioning "itself for a surge of federal spending on health information technology" by setting up a health IT strategy group. "Vangent is likely to face stiff competition for those dollars, but company officials say they expect the firm's reputation as a health-related services provider to serve it well as it bids on contracts." The firm is also involved in civil, defense and national security work, but health services are its largest business.

10 May 2010

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2010. During the quarter, the Company completed the sale of its specialty pharmaceutical business. This transaction has now transformed the Company, both financially and operationally, into a biopharmaceutical company dedicated to the discovery and development of oncology medicines.

10 May 2010

ACM receives Health Utilization Management Accreditation from URAC

Akeso Care Management®, Inc. (ACM®) announced today that it has been awarded Health Utilization Management Accreditation by URAC, a leading health care accrediting organization that establishes quality standards for the health care industry. ACM provides medical management services to domestic and international insurance carriers, self-insured employers and third party administrators.

10 May 2010

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

10 May 2010

Nearly half of IT security professionals believe personal healthcare information is less secure than before

Forty-seven percent of IT security professionals believe their personal healthcare information is less secure than it was 12 months ago according to a recent survey by nCircle, the leading provider of automated IT security and compliance auditing solutions.

10 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced it has enrolled the first patients in EFFICAS I, the first study of the EFFICAS series. These patients were enrolled in Na Homolce Hospital, Prague, Czech Republic and treated by Petr Neuzil, M.D. and Vivek Reddy, M.D.

10 May 2010

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Asthmatx, Inc. reported today that doctors at Virginia Hospital Center in Arlington, Va., recently treated the first U.S. patient with bronchial thermoplasty (BT) delivered by the Alair® System, the first device-based asthma treatment approved by the U.S. Food and Drug Administration (FDA).

10 May 2010

CFMG to adopt eClinicalWorks EMR system

eClinicalWorks®, a market leader in ambulatory clinical systems, today announced that California Forensic Medical Group (CFMG), which provides health care to correctional facilities in 25 counties in the state, has selected eClinicalWorks electronic medical records (EMR) system. Using eClinicalWorks will allow the group to streamline operations and improve the quality of care provided through reporting capabilities and the ability to share data across the counties. This will help in the continuity of care for inmates.

10 May 2010

Bovie Medical first-quarter revenues decrease to $5.6M

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2010.

10 May 2010

Health Canada approves BDSI's NDS for ONSOLIS

BioDelivery Sciences International, Inc. today announced the approval of a New Drug Submission (NDS) by Health Canada, the regulatory authority in Canada, for ONSOLIS (fentanyl buccal soluble film) in the management of breakthrough pain in opioid-tolerant adult patients with cancer. ONSOLIS is the first product approved in Canada for this indication.

10 May 2010

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the third quarter ended March 31, 2010. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

10 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

St. Jude Medical introduces Wireless USB Adaptor for Merlin@home transmitter in the U.S.

St. Jude Medical, Inc., a global medical device company, today announced the U.S. launch of its Wireless USB Adaptor for the Merlin@home™ transmitter, a system that allows important patient data from an implantable cardiac device to be wirelessly downloaded and securely transmitted via telephone for review by a physician. The new Wireless USB Adaptor enables patients using a Merlin@home transmitter to transmit data to their physician over cellular networks, allowing for more convenient care than existing landline services provide.

10 May 2010